Breaking News
- Smiths Detection Equips Phoenix Suns Arena With X-ray Inspection Systems
- SES Extends Long-Term Partnership With Sky
- Poplar Co. Ltd Switches to Rimini Street Support for SAP BusinessObjects and SAP Sybase IQ Database Software
- Ecoppia Strengthens Its Presence in the Middle East with a first Project in Egypt
- After a fashion: Designer Erdem Moralioglu outlines how Brexit has cost the UK industry dear
- 95% of UAE female leaders say more to be done about gender diversity at the top
- Yahsat bullish about growth as it plans to launch new satellite by 2024
- Tawazun to support Al Fattan Holding Investment’s shipyard expansion plans
- ADNOC prepares for launch of ICE Futures Abu Dhabi, new ICE Murban futures contract
- ADIO accelerates private sector investment, innovation collaboration with two Israeli government entities
- DLD completes 1.4 million digital services in 2020
- Dubai’s trade with Kuwait touches AED8.52 bn in H1- 2020
- Dubai South Properties launches The Pulse Villas
- UAE cabinet raises daily decline limit in shares to 10% from February 28
- Gulfood 2021 acclaimed for sending right ‘signals’ of return to normalcy
- No aircraft with PW4000 engines in UAE airspace: GCAA
- Ministry of Energy and Infrastructure joins 'Abu Dhabi Hydrogen Alliance'
- Sharjah Chamber of Commerce boosting economic ties with Egypt
- Hamriyah Free Zone signs investment agreement with Al Aliyo Hydrofarms at Gulfood 2021
- HCL Technologies Named a Prestigious World’s Best Employer by Forbes
- Colicity Inc. Announces Pricing of Upsized $300 Million Initial Public Offering
- Now Is the Best Time to Invest in Permanent Residency or Citizenship by Investment in Europe
- Jellyfish Acquires 5 Companies, Fueling Global Expansion With New Digital Capabilities
- Forest Devices Announces Positive Study Results for Their Stroke Detection Technology
- NHK WORLD-JAPAN Extends Multi-year Contract with SES on ASTRA 19.2 Degrees East
- Hillstone Networks Breaks Barriers for Data Center Security
- C3 AI Announces Upcoming Events for Financial Community
- HanesBrands Named One of the 2021 World’s Most Ethical Companies
- Yokogawa and ICQ Consultants Enter Into Partnership Agreement for Biopharmaceutical Business
- The Estée Lauder Companies to Increase Its Ownership in DECIEM
- Mavenir and Red Hat Collaborate to Transform Mobile Network Infrastructures
- Ethisphere Announces the 2021 World’s Most Ethical Companies
- AEB and EBC Channels Now Exclusively Broadcast via Ethiosat at 57 degrees East
- SES Networks to Power Ultimate Guest Connectivity Experience on Virgin Voyages’ Scarlet Lady
- CGTN:Targeted Poverty Alleviation - The Chinese Path to Fighting Poverty
- Additive Manufacturer Green Trade Association Announces New Members
- HRH Prince Mohammed bin Salman announces Soudah Development Company (SDC)
- Kia reveals K8, a modern innovative sedan
- EDGE, Lockheed Martin sign industrial partnership
- Qasimi delivers a choreographed mix of mens and womenswear for autumn / winter 2021
- UAE Central Bank joins Hong Kong government's digital currency project
- IHC opens new facility to process quarter of UAE’s seafood, supporting country’s food security aims
- Etisalat reports AED9 billion net profit in 2020
- CBUAE, HKMA enter fintech agreement
- Dubai Aerospace leases 7 Airbus A321neo aircraft to IndiGo
- UAE Armed Forces sign AED 17.913 billion worth of deals in three days at IDEX and NAVDEX
- Hatta Customs Center handled 966k tonnes of goods on board 75k trucks in 2020
- ADNOC's first CTO Roundtable discusses role of technology in shaping future of Oil & Gas industry
- UAE stock market liquidity up to AED1.33 bn as upbeat investors look past COVID-19
- MSCI to Launch Investment Solutions as a Service in Collaboration with Microsoft
LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States

First-In-Human Study Targeting the Endothelial Cell-expressed Adhesion Molecule VAP1
LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.
LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH). The phase 1 study is currently being conducted within the U.S. and approximately 64 subjects are expected to be enrolled.
“The commencement of this study is a significant landmark for LG Chem as we are determined to address the clear unmet needs of those with metabolic disease,” said Adam Benson, Director of Clinical Development of LG Chem Life Sciences Innovation Center in Cambridge, MA. “NASH to this day remains an elusive target. We feel strongly that LG00303174 has shown, in pre-clinical models, to have a strong safety profile, and as an oral therapy, has the potential to address a clear need in a disease that is becoming increasingly burdensome to our healthcare system.”
Dr. Frank Wu, CEO of TransThera, commented: “We congratulate LG Chem team on the rapid implementation of FIH trial in the United States, which marks a key milestone for this collaboration program.”
According to Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea, the fast and efficient implementation of this phase 1 study “is a testament to our clinical development capabilities of the LG Chem Life Sciences Innovation Center in Cambridge as a center of excellence to enrich and forward our development pipeline.”
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
LG Chem Life Sciences Innovation Center: innovation.lgchem.com
About TransThera Biosciences
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005934/en/
Top News

ADNOC Distribution reports AED2.4 billion net profit

Emaar Development delivers property sales of Dh6.308b

Dubai’s largest bank positive about UAE equity markets in 2021

Aster appoints Boucher as Global lead
